HomeCompareSPXCY vs JNJ

SPXCY vs JNJ: Dividend Comparison 2026

SPXCY yields 1.77% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 JNJ wins by $2.5K in total portfolio value· pulled ahead in Year 9
10 years
SPXCY
SPXCY
● Live price
1.77%
Share price
$30.50
Annual div
$0.54
5Y div CAGR
20%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$27.7K
Annual income
$1,461.08
Full SPXCY calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — SPXCY vs JNJ

📍 JNJ pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSPXCYJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SPXCY + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SPXCY pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SPXCY
Annual income on $10K today (after 15% tax)
$150.16/yr
After 10yr DRIP, annual income (after tax)
$1,241.92/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, JNJ beats the other by $2,744.07/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SPXCY + JNJ for your $10,000?

SPXCY: 50%JNJ: 50%
100% JNJ50/50100% SPXCY
Portfolio after 10yr
$29.0K
Annual income
$3,075.24/yr
Blended yield
10.60%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

SPXCY
No analyst data
Altman Z
10.0
Piotroski
7/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SPXCY buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSPXCYJNJ
Forward yield1.77%2.13%
Annual dividend / share$0.54$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR20%28%
Portfolio after 10y$27.7K$30.3K
Annual income after 10y$1,461.08$4,689.40
Total dividends collected$6.5K$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SPXCY vs JNJ ($10,000, DRIP)

YearSPXCY PortfolioSPXCY Income/yrJNJ PortfolioJNJ Income/yrGap
1$10,912$211.99$10,592$272.30+$320.00SPXCY
2$11,935$259.43$11,289$357.73+$646.00SPXCY
3$13,089$318.23$12,123$472.89+$966.00SPXCY
4$14,397$391.39$13,141$629.86+$1.3KSPXCY
5$15,887$482.80$14,408$846.81+$1.5KSPXCY
6$17,597$597.52$16,021$1,151.60+$1.6KSPXCY
7$19,571$742.22$18,122$1,588.22+$1.4KSPXCY
8$21,866$925.78$20,930$2,228.20+$936.00SPXCY
9← crossover$24,557$1,160.05$24,792$3,191.91$235.00JNJ
10$27,737$1,461.08$30,274$4,689.40$2.5KJNJ

SPXCY vs JNJ: Complete Analysis 2026

SPXCYStock

Singapore Exchange Limited, together with its subsidiaries, operates as an integrated securities and derivatives exchange, and related clearing houses in Singapore. It operates through Fixed Income, Currencies, and Commodities; Equities; and Data, Connectivity, and Indices segments. The Fixed Income, Currencies, and Commodities segment offers fixed income issuer, trading and clearing, and collateral management services. The Equities segment provides issuer, securities trading and clearing, securities settlement and depository management, derivatives trading and clearing, and collateral management services. The Data, Connectivity, and Indices segment offers market data, connectivity, and indices services. It also provides counterparty guarantee, and depository and related services for securities and derivatives transactions; bond trading services; front-line regulatory functions; computer and software maintenance; operates an electronic foreign exchange trading platform; and management consultancy services for index activities. In addition, the company offers membership and management services to related corporations; distributes bulk freight market indices and information; and operates an electricity market, as well as provides administration services for index calculation, risk analyses, and financial research. It has an agreement in relation to a global partnership to grow New Zealand's Exchange's dairy derivatives market together. Singapore Exchange Limited was incorporated in 1999 and is headquartered in Singapore.

Full SPXCY Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this SPXCY vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SPXCY vs SCHDSPXCY vs JEPISPXCY vs OSPXCY vs KOSPXCY vs MAINSPXCY vs ABBVSPXCY vs MRKSPXCY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.